Categories
Archives
- 2026
- 2025
- 2024
- 2023
Nov
09
Advancing Rheumatic Disease Treatment
Oct
31
NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters
Oct
17
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
Oct
17
Steadfast Towards Our Ambition to Create a UCB Rare Disease Portfolio
Oct
04
UCB presents late-breaking posters at Child Neurology Society Meeting
Sep
11
UCB PharmD Second-Year Fellows Share Reflections and Advice
Sep
05
Announcing the 2023 UCB Family Epilepsy Scholarship Winners
Aug
03
Employee Spotlight: David Hornbaker’s Heart for Helping Patients
Jul
21
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive
